Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation

22 de septiembre de 2014 actualizado por: AbbVie (prior sponsor, Abbott)

An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab (Humira®) in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation

This is an open-label study designed to establish the safety and effectiveness of adalimumab in the treatment of moderate to severe plaque psoriasis after 24 weeks of treatment.

Descripción general del estudio

Estado

Terminado

Intervención / Tratamiento

Descripción detallada

During the treatment period, participants will receive an initial adalimumab 80 milligram (mg) subcutaneous (sc) dose, followed by adalimumab 40 mg sc every other week starting one week after initial dose. Safety and effectiveness assessments will be completed at Baseline, Week 2, Week 4, Week 8, Week 12, Week 16 and Week 24. Participants may discontinue adalimumab treatment at any time during study participation. Participants that end study participation early will have a Premature Discontinuation visit. All participants who do not initiate commercial Humira® will have a follow-up phone call 70 days after the last administration of study drug to obtain information on any new or ongoing Adverse Events (AEs). The 70-day follow-up phone call will not be required for any participant that initiates adalimumab therapy not supplied in the context of the clinical trial after the end of study participation.

Tipo de estudio

Intervencionista

Inscripción (Actual)

50

Fase

  • Fase 4

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Ekaterinburg, Federación Rusa, 620076
        • Site Reference ID/Investigator# 67547
      • Kazan, Federación Rusa, 420012
        • Site Reference ID/Investigator# 78433
      • Moscow, Federación Rusa, 107076
        • Site Reference ID/Investigator# 67542
      • Saratov, Federación Rusa, 410028
        • Site Reference ID/Investigator# 67546
      • Smolensk, Federación Rusa, 214018
        • Site Reference ID/Investigator# 78417
      • St. Petersburg, Federación Rusa, 190013
        • Site Reference ID/Investigator# 78413
      • St. Petersburg, Federación Rusa, 194044
        • Site Reference ID/Investigator# 67545

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

A patient will be eligible for study participation if he/she meets the following criteria:

  1. Male and female patients ≥ 18 years of age.
  2. Clinical diagnosis of psoriasis for at least 6 months as determined by patient interview of his/her medical history and confirmation of diagnosis through physical examination by the investigator.
  3. Stable plaque psoriasis for at least 2 months before Screening and Baseline visits as determined by patient interview of his/her medical history.
  4. Moderate to severe plaque psoriasis defined by ≥ 10% Body Surface Area (BSA) involvement at the Baseline visit.
  5. PASI (Psoriasis Area and Severity Index) score ≥ 10 at the Baseline visit.

Exclusion Criteria:

  1. Diagnosis of erythrodermic psoriasis, pustular psoriasis, medication induced or medication-exacerbated psoriasis or new onset of guttate psoriasis.
  2. Diagnosis of other active skin diseases or skin infections (bacterial, fungal, or viral) that may interfere with evaluation of psoriasis.
  3. Patient who cannot discontinue topical therapies for the treatment of psoriasis such as corticosteroids, vitamin D analogs, or retinoids at least 14 days prior to the Baseline (Week 0) visit and during the study. Participants are allowed to use:

    • Shampoos that contain no corticosteroid;
    • Bland (without beta or alpha hydroxy acids or containing no psoriasis treatment) emollients;
    • Low potency topical corticosteroids on the palms, soles, face, inframammary area, and groin only.
  4. Patient who cannot avoid UVB (Ultraviolet-B) phototherapy for at least 14 days prior to the Baseline (Week 0) visit and during the study.
  5. Patient who cannot avoid PUVA (psoralen + ultraviolet A) phototherapy for at least 28 days prior to the Baseline (Week 0) visit and during the study.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Otro: Adalimumab
Participants received an initial adalimumab 80 mg subcutaneous dose, followed by adalimumab 40 mg subcutaneous every other week starting one week after the initial dose for up to 24 weeks.
Otros nombres:
  • ABT-D2E7
  • Humira

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Percentage of Participants Achieving a Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 24
Periodo de tiempo: Baseline and Week 24
The percentage of participants with a ≥ 75% reduction (improvement) in Psoriasis Area and Severity Index (PASI) score from Baseline. PASI is a combination of the intensity of psoriasis, assessed by the erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from no symptoms (0), slight (1), moderate (2), marked (3) or very marked (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease.
Baseline and Week 24

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Percentage of Participants Achieving a Physician's Global Assessment of Clear
Periodo de tiempo: Weeks 2, 4, 8, 12, 16 and 24

The Physician's Global Assessment (PGA) is a 6-point scale used to measure the severity of disease at the time of the qualified investigator's evaluation of the participant. The degree of overall lesion severity was evaluated using the following categories:

  • 0: No evidence of scaling, erythema, or plaque elevation, overall score of cleared;
  • 1: Occasional fine scale over <5% of lesions, faint erythema, minimal plaque elevation, overall score of minimal;
  • 2: Fine scale dominates, light red coloration, mild plaque elevation, overall score of mild;
  • 3: Course scale dominates, moderate red coloration, moderate plaque elevation, overall score of moderate;
  • 4: Thick non-tenacious scale dominates, bright red coloration, marked plaque elevation, overall score of marked;
  • 5: Very thick tenacious scale predominates, dusky to deep red coloration, severe plaque elevation, overall score of severe.

The percentage of participants achieving a PGA score of clear (0) is reported.

Weeks 2, 4, 8, 12, 16 and 24
Percentage of Participants Achieving a Physician's Global Assessment of Clear or Minimal
Periodo de tiempo: Weeks 2, 4, 8, 12, 16 and 24

The Physician's Global Assessment (PGA) is a 6-point scale used to measure the severity of disease at the time of the qualified investigator's evaluation of the participant. The degree of overall lesion severity was evaluated using the following categories:

  • 0: No evidence of scaling, erythema, or plaque elevation, overall score of cleared;
  • 1: Occasional fine scale over <5% of lesions, faint erythema, minimal plaque elevation, overall score of minimal;
  • 2: Fine scale dominates, light red coloration, mild plaque elevation, overall score of mild;
  • 3: Course scale dominates, moderate red coloration, moderate plaque elevation, overall score of moderate;
  • 4: Thick non-tenacious scale dominates, bright red coloration, marked plaque elevation, overall score of marked;
  • 5: Very thick tenacious scale predominates, dusky to deep red coloration, severe plaque elevation, overall score of severe.

The percentage of participants achieving a PGA score of clear (0) or minimal (1) is reported.

Weeks 2, 4, 8, 12, 16 and 24
Percentage of Participants Achieving a One Grade Improvement in Physician's Global Assessment (PGA)
Periodo de tiempo: Baseline and Weeks 2, 4, 8, 12, 16 and 24

The PGA is a 6-point scale used to measure the severity of disease at the time of the qualified investigator's evaluation of the participant. The degree of overall lesion severity was evaluated using the following categories:

  • 0: No evidence of scaling, erythema, or plaque elevation, overall score of cleared;
  • 1: Occasional fine scale over <5% of lesions, faint erythema, minimal plaque elevation, overall score of minimal;
  • 2: Fine scale dominates, light red coloration, mild plaque elevation, overall score of mild;
  • 3: Course scale dominates, moderate red coloration, moderate plaque elevation, overall score of moderate;
  • 4: Thick non-tenacious scale dominates, bright red coloration, marked plaque elevation, overall score of marked;
  • 5: Very thick tenacious scale predominates, dusky to deep red coloration, severe plaque elevation, overall score of severe.

The percentage of participants achieving a shift from Baseline to a less severe category is reported.

Baseline and Weeks 2, 4, 8, 12, 16 and 24
Percentage of Participants Achieving a PASI 50 Response
Periodo de tiempo: Baseline and Weeks 2, 4, 8, 12, 16, and 24
The percentage of participants with a ≥ 50% reduction (improvement) in Psoriasis Area and Severity Index (PASI) score from Baseline. PASI is a combination of the intensity of psoriasis, assessed by the erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from no symptoms (0), slight (1), moderate (2), marked (3) or very marked (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease.
Baseline and Weeks 2, 4, 8, 12, 16, and 24
Percentage of Participants Achieving a PASI 75 Response
Periodo de tiempo: Baseline and Weeks 2, 4, 8, 12, and 16
The percentage of participants with a ≥ 75% reduction (improvement) in Psoriasis Area and Severity Index (PASI) score from Baseline. PASI is a combination of the intensity of psoriasis, assessed by the erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from no symptoms (0), slight (1), moderate (2), marked (3) or very marked (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease.
Baseline and Weeks 2, 4, 8, 12, and 16
Percentage of Participants Achieving a PASI 90 Response
Periodo de tiempo: Baseline and Weeks 2, 4, 8, 12, 16, and 24
The percentage of participants with a ≥ 90% reduction (improvement) in Psoriasis Area and Severity Index (PASI) score from Baseline. PASI is a combination of the intensity of psoriasis, assessed by the erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from no symptoms (0), slight (1), moderate (2), marked (3) or very marked (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease.
Baseline and Weeks 2, 4, 8, 12, 16, and 24
Percentage of Participants Achieving a PASI 100 Response
Periodo de tiempo: Baseline and Weeks 2, 4, 8, 12, 16, and 24
The percentage of participants with a 100% reduction (improvement) in Psoriasis Area and Severity Index (PASI) score from Baseline. PASI is a combination of the intensity of psoriasis, assessed by the erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from no symptoms (0), slight (1), moderate (2), marked (3) or very marked (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease.
Baseline and Weeks 2, 4, 8, 12, 16, and 24
Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score
Periodo de tiempo: Baseline and Weeks 2, 4, 8, 12, 16, and 24

PASI is a combination of the intensity of psoriasis, assessed by the erythema (reddening), induration (plaque thickness) and desquamation (scaling) on a scale from no symptoms (0), slight (1), moderate (2), marked (3) or very marked (4), together with the percentage of the area affected, rated on a scale from 0 to 6. PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 to 72. The higher the total score, the more severe the disease.

Change from Baseline is presented as a percentage of the Baseline value: Post-baseline value - Baseline value / Baseline value * 100. A negative change from Baseline indicates improvement.

Baseline and Weeks 2, 4, 8, 12, 16, and 24
Percent Change From Baseline in Dermatology Life Quality Index (DLQI)
Periodo de tiempo: Baseline and Weeks 8, 12, and 24
The DLQI questionnaire asks participants to evaluate the degree that psoriasis has affected their quality of life in the last week, and includes the following parameters: symptoms and feelings, daily activities, leisure activities, work or school activities, personal relationships and treatment related feelings. Participants answer 10 questions on a scale from 0 (not at all) to 3 (very much); the range of the total score is 0 to 30. A score of 21 to 30 means an extremely large effect on the participant's life whereas 0-1 means that the disease has no effect at all. Change from Baseline is presented as a percentage of the Baseline value: Post-baseline value - Baseline value / Baseline value * 100. A negative change from Baseline indicates improvement.
Baseline and Weeks 8, 12, and 24
Percent Change From Baseline in Nail Psoriasis Severity Index (NAPSI)
Periodo de tiempo: Baseline and Week 24

NAPSI grades nails for both nail matrix psoriasis and nail bed psoriasis. The most affected fingernail was determined at Baseline and used for the analysis.

Nail matrix psoriasis consists of any of the following: pitting, leukonychia, red spots in the lunula, or nail plate crumbling. Nail bed psoriasis is the presence or absence of onycholysis, splinter hemorrhages, oil drop (salman patch) discoloration or nail bed hyperkeratosis. Scoring for each is based on the following scale:

  • 0 = none;
  • 1 = present in 1/4 nail quadrants;
  • 2 = present in 2/4 nail quadrants;
  • 3 = present in 3/4 nail quadrants;
  • 4 = present in 4/4 nail quadrants.

The sum of these two scores is the total score for the nail, and ranges from 0 (no nail psoriasis) to 8 (psoriasis in 4/4 nail quadrants). Change from Baseline is presented as a percentage of the Baseline value, calculated as: Week 24 value - Baseline value / Baseline value * 100. A negative change from Baseline indicates improvement.

Baseline and Week 24

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Change From Baseline in Hemoglobin
Periodo de tiempo: Baseline and Week 24 (or Early Termination Visit)
Safety variables included laboratory data, vital signs and adverse events.
Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Hematocrit
Periodo de tiempo: Baseline and Week 24 (or Early Termination Visit)
Safety variables included laboratory data, vital signs and adverse events. The hematocrit measures the volume of red blood cells compared to the total blood volume (red blood cells and plasma).
Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Red Blood Cell Count
Periodo de tiempo: Baseline and Week 24 (or Early Termination Visit)
Safety variables included laboratory data, vital signs and adverse events.
Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Blood Cell Counts
Periodo de tiempo: Baseline and Week 24 (or Early Termination Visit)
Safety variables included laboratory data, vital signs and adverse events.
Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Erythrocyte Sedimentation Rate
Periodo de tiempo: Baseline and Week 24 (or Early Termination Visit)
Safety variables included laboratory data, vital signs and adverse events.
Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Alanine Aminotransferase
Periodo de tiempo: Baseline and Week 24 (or Early Termination Visit)
Safety variables included laboratory data, vital signs and adverse events.
Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Aspartate Aminotransferase
Periodo de tiempo: Baseline and Week 24 (or Early Termination Visit)
Safety variables included laboratory data, vital signs and adverse events.
Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Alkaline Phosphatase
Periodo de tiempo: Baseline and Week 24 (or Early Termination Visit)
Safety variables included laboratory data, vital signs and adverse events.
Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Total Bilirubin
Periodo de tiempo: Baseline and Week 24 (or Early Termination Visit)
Safety variables included laboratory data, vital signs and adverse events.
Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Creatinine
Periodo de tiempo: Baseline and Week 24 (or Early Termination Visit)
Safety variables included laboratory data, vital signs and adverse events.
Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Blood Urea Nitrogen (BUN)
Periodo de tiempo: Baseline and Week 24 (or Early Termination Visit)
Safety variables included laboratory data, vital signs and adverse events.
Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Uric Acid
Periodo de tiempo: Baseline and Week 24 (or Early Termination Visit)
Safety variables included laboratory data, vital signs and adverse events.
Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Inorganic Phosphate
Periodo de tiempo: Baseline and Week 24 (or Early Termination Visit)
Safety variables included laboratory data, vital signs and adverse events.
Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Calcium, Sodium and Potassium
Periodo de tiempo: Baseline and Week 24 (or Early Termination Visit)
Safety variables included laboratory data, vital signs and adverse events.
Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Glucose
Periodo de tiempo: Baseline and Week 24 (or Early Termination Visit)
Safety variables included laboratory data, vital signs and adverse events.
Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Albumin
Periodo de tiempo: Baseline and Week 24 (or Early Termination Visit)
Safety variables included laboratory data, vital signs and adverse events.
Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Total Protein
Periodo de tiempo: Baseline and Week 24 (or Early Termination Visit)
Safety variables included laboratory data, vital signs and adverse events.
Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Cholesterol
Periodo de tiempo: Baseline and Week 24 (or Early Termination Visit)
Safety variables included laboratory data, vital signs and adverse events.
Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Triglycerides
Periodo de tiempo: Baseline and Week 24 (or Early Termination Visit)
Safety variables included laboratory data, vital signs and adverse events.
Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in High Sensitivity C-reactive Protein (hsCRP)
Periodo de tiempo: Baseline and Week 24 (or Early Termination Visit)
Safety variables included laboratory data, vital signs and adverse events.
Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Urine pH
Periodo de tiempo: Baseline and Week 24 (or Early Termination Visit)
Safety variables included laboratory data, vital signs and adverse events.
Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Urine Specific Gravity
Periodo de tiempo: Baseline and Week 24 (or Early Termination Visit)
Safety variables included laboratory data, vital signs and adverse events. Specific gravity is a measure of the amount of material dissolved in the urine. Specific gravity is the ratio of the density (mass of a unit volume) of a substance to the density (mass of the same unit volume) of a reference substance.
Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Blood Pressure
Periodo de tiempo: Baseline and Week 24 (or Early Termination Visit)
Safety variables included laboratory data, vital signs and adverse events.
Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Pulse
Periodo de tiempo: Baseline and Week 24 (or Early Termination Visit)
Safety variables included laboratory data, vital signs and adverse events.
Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Respiratory Rate
Periodo de tiempo: Baseline and Week 24 (or Early Termination Visit)
Safety variables included laboratory data, vital signs and adverse events.
Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Weight
Periodo de tiempo: Baseline and Week 24 (or Early Termination Visit)
Safety variables included laboratory data, vital signs and adverse events.
Baseline and Week 24 (or Early Termination Visit)
Change From Baseline in Body Temperature
Periodo de tiempo: Baseline and Week 24 (or Early Termination Visit)
Safety variables included laboratory data, vital signs and adverse events.
Baseline and Week 24 (or Early Termination Visit)
Number of Participants With Adverse Events (AEs)
Periodo de tiempo: From the first dose of study drug until 70 days after the last dose (up to 33 weeks).

An AE is any untoward medical occurrence, which does not necessarily have a causal relationship with treatment.

The investigator rated the severity of each AE as either:

Mild: The AE is transient and easily tolerated; Moderate: The AE causes the participant discomfort and interrupts usual activities.

Severe: The AE causes considerable interference with usual activities and may be incapacitating or life-threatening.

A serious adverse event (SAE) is an AE that results in death, is life-threatening, results in or prolongs hospitalization, results in congenital anomaly, persistent or significant disability/incapacity, spontaneous or elective abortion, or requires intervention to prevent a serious outcome.

Drug-related AEs are those assessed by the investigator as either probably or possibly related.

Other malignancy excludes lymphoma, hepatosplenic T-cell lymphoma (HSTCL), leukemia, non-melanoma skin cancer (NMSC), and melanoma.

From the first dose of study drug until 70 days after the last dose (up to 33 weeks).

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Director de estudio: Martin Okun, MD, AbbVie

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Enlaces Útiles

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio

1 de mayo de 2012

Finalización primaria (Actual)

1 de septiembre de 2013

Finalización del estudio (Actual)

1 de septiembre de 2013

Fechas de registro del estudio

Enviado por primera vez

7 de mayo de 2012

Primero enviado que cumplió con los criterios de control de calidad

17 de julio de 2012

Publicado por primera vez (Estimar)

19 de julio de 2012

Actualizaciones de registros de estudio

Última actualización publicada (Estimar)

1 de octubre de 2014

Última actualización enviada que cumplió con los criterios de control de calidad

22 de septiembre de 2014

Última verificación

1 de septiembre de 2014

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • M13-279

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Ensayos clínicos sobre Adalimumab

3
Suscribir